Page 84 - Read Online

Guerriero et al. Hepatoma Res 2019;5:6 I http://dx.doi.org/10.20517/2394-5079.2018.108 Page 17 of 22

Albeit often very exciting, results from the scientific literature are so far inconsistent. To change this status
and open the way to translational applications, prospective well-designed large multicenter trials are needed.

DECLARATIONS
Authors’ contributions
Conceived and designed the study: Callegari E, Sabbioni S, Negrini M
Wrote the manuscript: Guerriero P, Moshiri F, Lupini L, Callegari E, Negrini M
Read and approved the manuscript: All authors

Availability of data and materials
Not applicable.

Financial support and sponsorship
This work was supported by funds from the Italian Association for Cancer Research and from the University
of Ferrara to Negrini M.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2019.

REFERENCES
1. Llovet JM, Fuster J, Bruix J; Barcelona-Clinic Liver Cancer G. The Barcelona approach: diagnosis, staging, and treatment of
hepatocellular carcinoma. Liver Transpl 2004;10:S115-20.
2. Tabrizian P, Jibara G, Shrager B, Schwartz M, Roayaie S. Recurrence of hepatocellular cancer after resection: patterns, treatments, and
prognosis. Ann Surg 2015;261:947-55.
3. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-2.
4. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves
survival. Hepatology 2003;37:429-42.
5. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med
2008;359:378-90.
6. Spangenberg HC, Thimme R, Blum HE. Serum markers of hepatocellular carcinoma. Semin Liver Dis 2006;26:385-90.
7. Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound
alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 2009;137:110-8.
8. McMahon BJ, Bulkow L, Harpster A, Snowball M, Lanier A, et al. Screening for hepatocellular carcinoma in Alaska natives infected
with chronic hepatitis B: a 16-year population-based study. Hepatology 2000;32:842-6.
9. Chen JG, Parkin DM, Chen QG, Lu JH, Shen QJ, et al. Screening for liver cancer: results of a randomised controlled trial in Qidong,
China. J Med Screen 2003;10:204-9.
10. Volk ML, Hernandez JC, Su GL, Lok AS, Marrero JA. Risk factors for hepatocellular carcinoma may impair the performance of
biomarkers: a comparison of AFP, DCP, and AFP-L3. Cancer Biomark 2007;3:79-87.
11. Grizzi F, Franceschini B, Hamrick C, Frezza EE, Cobos E, et al. Usefulness of cancer-testis antigens as biomarkers for the diagnosis
and treatment of hepatocellular carcinoma. J Transl Med 2007;5:3.
12. Marrero JA, Su GL, Wei W, Emick D, Conjeevaram HS, et al. Des-gamma carboxyprothrombin can differentiate hepatocellular
carcinoma from nonmalignant chronic liver disease in american patients. Hepatology 2003;37:1114-21.
13. Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, et al. Hepatocellular carcinoma. Nat Rev Dis Primers 2016;2:16018.
14. Lamerz R, Runge M, Stieber P, Meissner E. Use of serum PIVKA-II (DCP) determination for differentiation between benign and
malignant liver diseases. Anticancer Res 1999;19:2489-93.
15. Yan L, Chen Y, Zhou J, Zhao H, Zhang H, et al. Diagnostic value of circulating cell-free DNA levels for hepatocellular carcinoma. Int